Second Opinion: Obstructive Hypertrophic Cardiomyopathy

Practical Cardiology advisory board members sit down with the director of Center for Inherited Cardiac Disease at Penn Medicine, Dr. Anjali Owens, to talk about the current state of management for obstructive hypertrophic cardiomyopathy, often referred to as oHCM, and how the FDA approval of mavacamten might impact care moving forward.